To ensure market access is integrated with other functions and across geographies, and is an early part of future drug development, companies must understand what is required, internally and ...

The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.

The journey to global market access for innovative therapies is ... have traditionally relied upon clinical trials for drug development, real-world evidence (RWE) has become a vital source of ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

The industry's research and development has saved and improved ... of Ozempic and Wegovy and allowed the copycat drugs access to the market. But there is no shortage today. The FDA moved those ...

Despite having a robust drug development pipeline, lupus remains far behind other rheumatic and autoimmune conditions for which dozens of targeted therapies have been developed. Addressing the ...

The incentive to invest in drug development disappears ... and make it harder for patients to access medicines that are already on the market. Consider what has happened in the UK, which requires ...